Anavex Life Sciences Corp (AVXL)

[sokol]

I fully agree. We have done the work, which indicates the science behind this class of drugs is an answer to treating CNS diseases. It is new, relatively unknown, and in the long drawn-out process of validation. Exercising patience is the key. If you are right, sit tight. Don't become impatient and lose your position or as some have said to keep a core position.

I believe we need to manage our expectations. What may seem to be obvious to us is foreign to others. All of these "others" out there will likely approach any new and encouraging developments with suspicion.